Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.125.322774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Aurélien Philippe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Cité, Institut national de la santé et de la recherche médicale (INSERM), Paris Cardiovascular Research Center (PARCC), France (A.P.…. Hauptthemen laut MEDLINE: Dexamethasone, COVID-19, COVID-19 Drug Treatment, Blood Coagulation Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Endotheliopathy and coagulopathy are known complications of COVID-19, with a significant association with mortality. Although dexamethasone is the standard of care for patients with severe COVID-19, its precise mode of action remains elusive. We aim to investigate the functional consequences of dexamethasone treatment on COVID-19–associated procoagulant endotheliopathy. METHODS: First, during the 7 days after hospitalization, we measured several endothelial and coagulopathy biomarkers in a prospective cohort of patients with COVID-19 with acute respiratory distress syndrome (ARDS) who were either treated or not with both dexamethasone and therapeutic UFH (unfractionated heparin). Second, we developed an in vitro thrombin generation assay on cultured human endothelial cells to measure the ability of stimulated endothelial colony-forming cells to activate coagulation in normal plasma, which is expressed as an endogenous thrombin potential (ETP). RESULTS: Among the cohort of 44 ARDS COVID-19 patients, 23 patients treated with dexamethasone and therapeutic UFH had significantly decreased von Willebrand Factor, Ang-2 (angiopoietin-2), soluble E-selectin, and d -dimer levels over 7 days. To differentiate the effect of UFH and dexamethasone on endotheliopathy, we used the thrombin generation assay and showed that endothelial colony-forming cell stimulation with dexamethasone but not UFH—in addition to a cocktail of proinflammatory cytokines (to mimic the cytokine storm of severe COVID-19)—significantly decreased ETP in comparison to proinflammatory cytokines only. Moreover, in another cohort of 331 patients with COVID-19 of varying severity, the endothelial colony-forming cell stimulation with the plasma of 87 ARDS patients showed significantly higher ETP (1260 nmol/L per minute [interquartile range, 1140–1260]) compared with 75 non-ARDS patients (1024 nmol/L per minute [interquartile range, 915–1200]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Cité, Institut national de la santé et de la recherche médicale (INSERM), Paris Cardiovascular Research Center (PARCC), France (A.P., N.G., X.L., J.R., L.K., O.S., C.M.B., J.-L.D., D.M.S.).
- Hematology Department, AP-HP (A.P., N.G., J.R., D.M.S.), Assistance Publique - Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
- Intensive Care Medicine Department (R.Y., N.P., C.H.-B., B.H., J.-L.D.), Assistance Publique - Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
- UNIROUEN, Institut national de la santé et de la recherche médicale (INSERM) U1096 EnVI, Normandie University, Rouen, France (P.B.).
- Vascular Medicine Department (L.K.), Assistance Publique - Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
- Respiratory Diseases Department (O.S.), Assistance Publique - Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
ORCID-Profile: Aurélien Philippe, Romy Younan, Paul Billoir, Bertrand Hermann, Olivier Sanchez, Gilles Chatelier, Chantal M Boulanger, Jean-Luc Diehl, David M Smadja
Zitieren
APA
Philippe, A., Younan, R., Gendron, N., Peron, N., Loyer, X., Rancic, J., Hauw-Berlemont, C., Billoir, P., Hermann, B., Khider, L., Sanchez, O., Chatelier, G., Boulanger, C. M., Diehl, J. L., & Smadja, D. M. (2025). Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.322774
Vancouver
Philippe A, Younan R, Gendron N, Peron N, Loyer X, Rancic J, et al. Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.125.322774
BibTeX
@article{Philippe2025,
author = {Philippe, Aurélien and Younan, Romy and Gendron, Nicolas and Peron, Nicolas and Loyer, Xavier and Rancic, Jeanne and Hauw-Berlemont, Caroline and Billoir, Paul and Hermann, Bertrand and Khider, Lina and Sanchez, Olivier and Chatelier, Gilles and Boulanger, Chantal M and Diehl, Jean-Luc and Smadja, David M},
title = {Dexamethasone Suppresses Endotheliopathy and Endothelial-Induced Coagulopathy in COVID-19},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.125.322774}
}
EUVIMED